David D. Berg

Dec 28, 2023 | jamanetwork.com | David D. Berg |Pardeep S. Jhund |Kieran F. Docherty |Sabina A. Murphy

Key PointsQuestion  When does the clinical benefit of dapagliflozin emerge in patients with heart failure with reduced ejection fraction, and what is the magnitude as a function of proximity to prior heart failure hospitalization? Findings  In this secondary analysis of a randomized clinical trial, dapagliflozin rapidly reduced the risk of cardiovascular death or worsening heart failure, with a sustained statistically significant benefit as soon as 28 days.